A multi-centre randomised trial of standard or higher targets for transfusion during chemo-radiation of cervix cancer.
A phase III feasibility study to evaluate the difference in average weekly haemoglobin concentrations between experimental and control groups and the impact of red cell concentrate transfusion of maintaining haemoglobin levels above 120g/l versus above 100g/l in anaemic patients with carcinoma of the cervix receiving concurrent cisplatin and radiation therapy.
Investigator initiated trial (name of investigator is Dr Michelle Grogan) coordinated by the University of Sydney.
100 participants
Jul 5, 2006
Interventional
Conditions
Summary
To assess whether raising haemoglobin (red blood cells that carry oxygen throughout the body) levels during treatment can improve patient quality of life and treatment effectiveness.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive red cell concentrate transfusion to maintain their haemoglobin at pre-specified levels. Experimental Group From 120g/l Hb to 130g/l Hb. All patients receive external beam pelvic radiation with concurrent weekly cisplatin 40mg/m2 followed by intracavity radiation. External pelvic radiation +/- intracavity radiation with concomitant weekly cisplatin 40mg/m2 delivered intravenously on days 1,8,15,22,29 and once during parametrial boost (if given). Ideally all treatment should be completed within 8 weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000167561